バイオシミラーモノクローナル抗体の世界市場レポート 2025年

バイオシミラーモノクローナル抗体市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.5％で127億9,000万米ドルに成長します。予測期間の成長は、生物学的製剤の支出増加、バイオシミラーポートフォリオの拡大、バイオシミラー治療の個別化、バイオシミラーに対する社会的関心の高まりに起因しています。予測期間の主な動向には、治療法の拡大、バイオシミラーの個別化、共同研究・提携、バイオシミラー自動注射器・デバイス、バイオベッターが含まれます。

慢性疾患の増加はバイオシミラーモノクローナル抗体市場を押し上げると予想されます。これらのバイオシミラーモノクローナル抗体は、がん、自己免疫疾患、関節リウマチなどの慢性疾患の治療に利用されています。がん治療では、トラスツズマブ、ベバシズマブ、リツキシマブなどのモノクローナル抗体のバイオシミラーが一般的に使用されています。さらに、がんの罹患率は年々上昇し続けています。例えば、2024年2月、米国の公衆衛生機関である疾病対策予防センター（CDC）の報告によると、複数の慢性疾患を抱える米国人が増加しており、42％が2つ以上の疾患を抱え、12％が5つ以上の疾患を抱えています。その結果、慢性疾患の有病率の増加がバイオシミラーモノクローナル抗体市場の拡大を促進すると予想されます。

老年人口の増加もバイオシミラーモノクローナル抗体市場を牽引します。これらの抗体は、重要な治療法への費用対効果の高いアクセスを提供し、慢性疾患と闘う高齢者の治療費と生活の質を向上させます。世界保健機構（WHO）の推計によると、高齢者人口は大幅に増加しており、2050年には世界で21億人の高齢者が生まれると予測されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バイオシミラーモノクローナル抗体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のバイオシミラーモノクローナル抗体市場：成長率分析
• 世界のバイオシミラーモノクローナル抗体市場の実績：規模と成長, 2019-2024
• 世界のバイオシミラーモノクローナル抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界バイオシミラーモノクローナル抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオシミラーモノクローナル抗体市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 合成化学物質
• バイオ医薬品
• その他のタイプ
• 世界のバイオシミラーモノクローナル抗体市場化合物別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インフリキシマブ
• リツキシマブ
• アブシキシマブ
• トラスツズマブ
• アダリムマブ
• ベバシズマブ
• 世界のバイオシミラーモノクローナル抗体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性疾患および自己免疫疾患
• 腫瘍学
• その他の用途
• 世界のバイオシミラーモノクローナル抗体市場合成化学物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子医薬品
• 化学合成製品
• 世界のバイオシミラーモノクローナル抗体市場バイオ医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 組み換えタンパク質
• ワクチン
• その他のバイオ医薬品
• 世界のバイオシミラーモノクローナル抗体市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗体薬物複合体
• 融合タンパク質
• 他の生物学的製剤のバイオシミラー

第7章 地域別・国別分析

• 世界のバイオシミラーモノクローナル抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオシミラーモノクローナル抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラーモノクローナル抗体市場：競合情勢
• バイオシミラーモノクローナル抗体市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Coherus BioSciences Overview, Products and Services, Strategy and Financial Analysis
  • Biocon Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Celltrion Inc.
• BioXpress Therapeutics SA
• Intas Pharmaceuticals Limited
• Genor BioPharma Co. Ltd.
• BIOCAD
• Dr. Reddy's Laboratories Ltd.
• 3SBio Inc.
• Reliance Life Sciences
• Hisun Pharmaceuticals
• Celgen Biopharmaceuticals
• Torrent Pharmaceuticals Ltd.
• Cadila Healthcare Ltd.
• Shanghai Henlius Biotech Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオシミラーモノクローナル抗体市場2029：新たな機会を提供する国
• バイオシミラーモノクローナル抗体市場2029：新たな機会を提供するセグメント
• バイオシミラーモノクローナル抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Biosimilar monoclonal antibodies belong to a subset of biosimilars known for their role in treating conditions like cancer or rheumatoid arthritis. These intricate proteins are integral in the immune system's function, identifying and eliminating foreign substances such as bacteria and viruses.

Within the category of biosimilar monoclonal antibodies, key types include synthetic chemicals, biopharmaceuticals, and others. Biopharmaceuticals, often referred to as biologic medical products, are pharmaceutical drugs derived from biological sources or semi-synthesized compounds. Notable compounds in this category include infliximab, rituximab, abciximab, trastuzumab, adalimumab, and bevacizumab. They find applications across various medical domains including chronic and autoimmune diseases, oncology, and other therapeutic areas. These biosimilar monoclonal antibodies play a crucial role in addressing a wide spectrum of health conditions.

The biosimilar monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides biosimilar monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a biosimilar monoclonal antibodies market share, detailed biosimilar monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar monoclonal antibodies industry. This biosimilar monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2024 to $9.25 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to patent expirations, growing awareness of biosimilars, government initiatives, increasing investment from pharmaceutical companies, and growing acceptance of biosimilars by clinicians and patients.

The biosimilar monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.79 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising biologic expenditure, biosimilar portfolio expansion, personalization of biosimilar therapy, and increasing public interest in biosimilars. Major trends in the forecast period include therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, biobetters.

The rising prevalence of chronic diseases is anticipated to boost the biosimilar monoclonal antibodies market. These biosimilar monoclonal antibodies are utilized in the treatment of chronic conditions such as cancer, autoimmune diseases, and rheumatoid arthritis. In cancer therapy, biosimilars for monoclonal antibodies, including trastuzumab, bevacizumab, and rituximab, are commonly employed. Additionally, the incidence of cancer continues to rise each year. For instance, in February 2024, reports from the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, indicated that an increasing number of Americans are managing multiple chronic conditions, with 42% experiencing two or more conditions and 12% dealing with five or more. Consequently, the growing prevalence of chronic diseases is expected to drive the expansion of the biosimilar monoclonal antibodies market.

The growing geriatric population is also set to drive the biosimilar monoclonal antibodies market. These antibodies offer cost-effective access to vital therapies, enhancing treatment affordability and quality of life for older adults combating chronic diseases. The World Health Organization's estimates indicate a substantial rise in the elderly population, with projections of 2.1 billion elderly individuals globally by 2050, illustrating the significance of biosimilar monoclonal antibodies in catering to the healthcare needs of this demographic.

Major companies in the biosimilar monoclonal antibodies market are concentrating on the development of cost-effective biosimilar therapies to secure a competitive edge. These therapies are biologic medical products that are highly similar to already approved reference monoclonal antibodies, aimed at providing affordable treatment options for various conditions, including cancer and autoimmune diseases. For example, in 2022, Pfizer, a U.S.-based pharmaceutical company, launched Abrilada, a biosimilar of AbbVie's Humira (adalimumab). Abrilada offers a comparable efficacy and safety profile to the original product while delivering significant cost savings for both patients and healthcare systems. Furthermore, it benefits from a streamlined approval process and robust manufacturing capabilities, which improve patient access to essential treatments. This trend reflects a broader industry movement towards tackling rising healthcare costs while ensuring high-quality therapeutic options are available for patients.

Leading companies in the biosimilar monoclonal antibody market are creating biosimilar versions of monoclonal antibodies to provide cost-effective alternatives to original therapies, thereby enhancing access and affordability in healthcare. An intravenous formulation is specifically designed to be administered directly into the bloodstream via a vein for a rapid therapeutic effect. For example, in May 2024, Bio-Thera Solutions, a biopharmaceutical company based in China, in collaboration with Biogen Inc., a U.S.-based biopharmaceutical company, launched TOFIDENCE (tocilizumab-bavi) in an intravenous formulation in the United States. The U.S. Food and Drug Administration approved TOFIDENCE in September 2023 for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. Upon launch, TOFIDENCE is available in three vial sizes-80 mg/4 mL, 200 mg/10 mL, and 400 mg/20 mL-designed for intravenous infusion, with plans for subcutaneous formulations to be released in the future.

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, successfully acquired Viatris Inc.'s biosimilars business, marking a significant strategic move. The acquisition, though the financial details were undisclosed, positions Biocon Biologics closer to patients, customers, and payors, enhancing their direct commercial capabilities and bolstering infrastructure in both advanced markets and several emerging regions.

Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.

North America was the largest region in the biosimilar monoclonal antibodies market in 2024. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar monoclonal antibodies market consists of sales of Blitzima, Ritemvia, Rituzena, and Truxima. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilar Monoclonal Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilar monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilar monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilar monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Synthetic Chemicals; Biopharmaceuticals; Other Types
• 2) By Compound: Infliximab; Rituximab; Abciximab; Trastuzumab; Adalimumab; Bevacizumab
• 3) By Application: Chronic & Autoimmune Diseases; Oncology; Other Applications
• Subsegments:
• 1) By Synthetic Chemicals: Small Molecule Drugs; Chemical Synthesis Products
• 2) By Biopharmaceuticals: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Other Biopharmaceuticals
• 3) By Other Types: Antibody-Drug Conjugates; Fusion Proteins; Biosimilars Of Other Biologics
• Companies Mentioned: Pfizer Inc.; Novartis AG; AbbVie Inc.; Coherus BioSciences; Biocon Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilar Monoclonal Antibodies Market Characteristics

3. Biosimilar Monoclonal Antibodies Market Trends And Strategies

4. Biosimilar Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Biosimilar Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Biosimilar Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Biosimilar Monoclonal Antibodies Market Growth Rate Analysis
• 5.4. Global Biosimilar Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Biosimilar Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Biosimilar Monoclonal Antibodies Total Addressable Market (TAM)

6. Biosimilar Monoclonal Antibodies Market Segmentation

• 6.1. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic Chemicals
• Biopharmaceuticals
• Other Types
• 6.2. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab
• 6.3. Global Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic & Autoimmune Diseases
• Oncology
• Other Applications
• 6.4. Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Synthetic Chemicals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Drugs
• Chemical Synthesis Products
• 6.5. Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Biopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biopharmaceuticals
• 6.6. Global Biosimilar Monoclonal Antibodies Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibody-Drug Conjugates
• Fusion Proteins
• Biosimilars Of Other Biologics

7. Biosimilar Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Biosimilar Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Biosimilar Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biosimilar Monoclonal Antibodies Market

• 8.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biosimilar Monoclonal Antibodies Market

• 9.1. China Biosimilar Monoclonal Antibodies Market Overview
• 9.2. China Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biosimilar Monoclonal Antibodies Market

• 10.1. India Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biosimilar Monoclonal Antibodies Market

• 11.1. Japan Biosimilar Monoclonal Antibodies Market Overview
• 11.2. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biosimilar Monoclonal Antibodies Market

• 12.1. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biosimilar Monoclonal Antibodies Market

• 13.1. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biosimilar Monoclonal Antibodies Market

• 14.1. South Korea Biosimilar Monoclonal Antibodies Market Overview
• 14.2. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biosimilar Monoclonal Antibodies Market

• 15.1. Western Europe Biosimilar Monoclonal Antibodies Market Overview
• 15.2. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biosimilar Monoclonal Antibodies Market

• 16.1. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biosimilar Monoclonal Antibodies Market

• 17.1. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biosimilar Monoclonal Antibodies Market

• 18.1. France Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biosimilar Monoclonal Antibodies Market

• 19.1. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biosimilar Monoclonal Antibodies Market

• 20.1. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biosimilar Monoclonal Antibodies Market

• 21.1. Eastern Europe Biosimilar Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biosimilar Monoclonal Antibodies Market

• 22.1. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biosimilar Monoclonal Antibodies Market

• 23.1. North America Biosimilar Monoclonal Antibodies Market Overview
• 23.2. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biosimilar Monoclonal Antibodies Market

• 24.1. USA Biosimilar Monoclonal Antibodies Market Overview
• 24.2. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biosimilar Monoclonal Antibodies Market

• 25.1. Canada Biosimilar Monoclonal Antibodies Market Overview
• 25.2. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biosimilar Monoclonal Antibodies Market

• 26.1. South America Biosimilar Monoclonal Antibodies Market Overview
• 26.2. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biosimilar Monoclonal Antibodies Market

• 27.1. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biosimilar Monoclonal Antibodies Market

• 28.1. Middle East Biosimilar Monoclonal Antibodies Market Overview
• 28.2. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biosimilar Monoclonal Antibodies Market

• 29.1. Africa Biosimilar Monoclonal Antibodies Market Overview
• 29.2. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Compound, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Biosimilar Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biosimilar Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Biosimilar Monoclonal Antibodies Market Competitive Landscape
• 30.2. Biosimilar Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Coherus BioSciences Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis

31. Biosimilar Monoclonal Antibodies Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Celltrion Inc.
• 31.4. BioXpress Therapeutics SA
• 31.5. Intas Pharmaceuticals Limited
• 31.6. Genor BioPharma Co. Ltd.
• 31.7. BIOCAD
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. 3SBio Inc.
• 31.10. Reliance Life Sciences
• 31.11. Hisun Pharmaceuticals
• 31.12. Celgen Biopharmaceuticals
• 31.13. Torrent Pharmaceuticals Ltd.
• 31.14. Cadila Healthcare Ltd.
• 31.15. Shanghai Henlius Biotech Inc.

32. Global Biosimilar Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biosimilar Monoclonal Antibodies Market

34. Recent Developments In The Biosimilar Monoclonal Antibodies Market

35. Biosimilar Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

• 35.1 Biosimilar Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Biosimilar Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Biosimilar Monoclonal Antibodies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer